MRI computer-aided detection developer CAD Sciences of White Plains, NY, has signed a deal with Sapheneia of Jackson, MS, to develop a product for analyzing suspicious lung lesions with ultralow-dose CT.
The agreement would adapt CAD Sciences' fTP (full-time-point) pharmacokinetic analysis software platform, currently used for MRI breast and prostate CAD, to CT studies of lung disease. Sapheneia is contributing its ultralow-dose CT technology, which permits lower-dose acquisition of CT images while reducing patient exposure to radiation without the customary reduction in image quality, according to the companies.
The companies believe that their application of pharmacokinetic analysis of contrast characteristics in low-dose CT images is unique. The combined product will overcome the dual complication posed by the radiation component of CT, which limits image acquisition according to maximum acceptable dose parameters, and the conflicting need for image acquisition at multiple time points, which is a key ingredient to fTP technology, the companies said.
While the integrated ultralow-dose CT/fTP product is currently under development, the commercial-ready version of the product will ultimately reside on CAD Sciences' Server2 product as an optional module for which a customer may obtain a separate usage license, similar to the company's breast and prostate software modules. Server2 enables automatic processing of image data on a server attached to the imaging facility's PACS network.
By AuntMinnie.com staff writers
May 24, 2006
Related Reading
CAD Sciences unveils new releases, May 10, 2006
CAD Sciences seeks European expansion, February 1, 2006
CPT code released for breast MRI CAD, January 10, 2006
CAD Sciences adds BI-RADS support, December 22, 2005
CAD Sciences, Hitachi partner on MR protocol, December 1, 2005
Copyright © 2006 AuntMinnie.com
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)